Gastric Adenocarcinoma clinical trials at UCSD

1 in progress, 0 open to eligible people

INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Sorry, not currently recruiting here
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
San Diego, California and other locations

Our lead scientists for Gastric Adenocarcinoma research studies include Adam Burgoyne, MD.

Last updated: August 4, 2023

INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas